medRxiv - Endocrinology最新文献

{"title":"Parameter estimation for the oral minimal model and parameter distinctions between obese and non-obese type 2 diabetes","authors":"Manoja Rajalakshmi Aravindakshan, Devleena Ghosh, Chittaranjan Mandal, K V Venkatesh, Jit Sarkar, Partha Chakrabarti, Sujay K Maity","doi":"10.1101/2024.04.06.24305200","DOIUrl":"https://doi.org/10.1101/2024.04.06.24305200","url":null,"abstract":"Oral Glucose Tolerance Test (OGTT) is the primary test used to diagnose type 2 diabetes mellitus (T2DM) in a clinical setting. Analysis of OGTT data using the Oral Minimal Model (OMM) along with the rate of appearance of ingested glucose (<em>R</em>_a) is performed to study differences in model parameters for control and T2DM groups. The differentiation of parameters of the model gives insight into the behaviour and physiology of T2DM. The model is also studied to find parameter differences among obese and non-obese T2DM subjects and the sensitive parameters were co-related to the known physiological findings. Sensitivity analysis is performed to understand changes in parameter values with model output and to support the findings, appropriate statistical tests are done. This seems to be the first preliminary application of the OMM with obesity as a distinguishing factor in understanding T2DM from estimated parameters of insulin-glucose model and relating the statistical differences in parameters to diabetes pathophysiology.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140578031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Anemia on Prevalence of Gestational Diabetes among Pregnant Women in Tripoli, Libya","authors":"Ahmed Atia, Hosam Elmahmoudi","doi":"10.1101/2024.04.07.24305457","DOIUrl":"https://doi.org/10.1101/2024.04.07.24305457","url":null,"abstract":"Gestational diabetes mellitus (GDM) is raised globally leading to substantial maternal and foetal morbidity. This study aimed to determine the prevalence of GDM among pregnant women delivering in different private polyclinics in Tripoli, Libya. A cross-sectional study was conducted among pregnant women who were admitted to gynecology department of in different medical polyclinics, Tripoli, Libya from Jan to Dec 2022. The prevalence of GDM in pregnant women increased with increase of the gestational age to reach maximum (86%) at the third trimester of gestation. About 31% (96 patients) anemic pregnant women were observed in 312 GDM. Careful surveillance is required for these pregnancies in high-risk units for early detection and treatment of possible complications, in order to try to reduce maternal and neonatal morbidities.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140577896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete loss of SLC30A8 in humans improves glucose metabolism and beta cell function","authors":"Lindsey B. Lamarche, Christopher Koch, Shareef Khalid, Maleeha Zaman, Richard Zessis, Matthew E. Clement, Daniel P. Denning, Allison B. Goldfine, Ali Abbasi, Jennifer L Harrow, Christina Underwood, Kazuhisa Tsunoyama, Makoto Asaumi, Ikuyo Kou, Juan L Rodriguez-Flores, Alan R. Shuldiner, Asif Rasheed, Muhammad Jahanzaib, Muhammad Rehan Mian, Muhammad Bilal Liaqat, Usman Abdulsalam, Riffat Sultana, Anjum Jalal, Muhammad Hamid Saeed, Shahid Abbas, Fazal Rehman Memon, Muhammad Ishaq, Allan M. Gurtan, John E. Dominy, Danish Saleheen","doi":"10.1101/2024.04.05.24305397","DOIUrl":"https://doi.org/10.1101/2024.04.05.24305397","url":null,"abstract":"Genetic association studies have demonstrated that partial loss of <em>SLC30A8</em> function protects against type 2 diabetes (T2D) in humans, but the impact of complete loss of <em>SLC30A8</em> function remains unknown. From whole-exome and genome sequencing of 100,814 participants in the Pakistan Genome Resource, we identified fifteen <em>SLC30A8</em> knockouts, including homozygotes for a variant enriched in South Asians (Gln174Ter) and 615 heterozygotes for loss-of-function (LoF) variants. T2D risk was lower in <em>SLC30A8</em> LoF hetero- and homozygotes, and the protective effect strengthens in a gene dose-dependent manner (OR_additive=0.63 [0.53-0.78, p=7.5E-07], OR_recessive=0.27 [0.09-0.80, p=0.018]). Recall-by-genotype of <em>SLC30A8</em> LoF hetero- and homozygotes and their family members with oral glucose tolerance tests showed a gene dose-dependent reduction in glucose levels coupled with elevated insulin. Corrected Insulin Response, Disposition Index, and Insulin Sensitivity Index in LoF hetero- and homozygotes indicated higher glucose-stimulated insulin secretion with preserved beta cell function. These data suggest that therapeutic knockdown of <em>SLC30A8</em>, up to and including complete knockout, may treat T2D safely and effectively.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140578106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential manifestation of type 2 diabetes in Black Africans and White Europeans with recently diagnosed type 2 diabetes: A systematic review","authors":"Davis Kibirige, Ronald Olum, Andrew Peter Kyazze, Bethan Morgan, Felix Bongomin, William Lumu, Moffat Joha Nyirenda","doi":"10.1101/2024.03.26.24304917","DOIUrl":"https://doi.org/10.1101/2024.03.26.24304917","url":null,"abstract":"Aims\u0000The clinical manifestation of type 2 diabetes (T2D) varies across populations. We compared the phenotypic characteristics of Black Africans and White Europeans with recently diagnosed T2D to understand the ethnic differences in the manifestation of T2D.\u0000Methods\u0000We searched Medline, EMBASE, CINAHL, Google Scholar, African Index Medicus, and Global Health for studies reporting information on phenotypic characteristics in Black Africans and White Europeans with recently diagnosed T2D. Results\u0000A total of 26 studies were included in this systematic review. Of these, 12 studies and 14 studies were conducted on 2,586 Black Africans in eight countries and 279,621 White Europeans in nine countries, respectively. Compared with White Europeans, Black Africans had a lower pooled mean age (49.4 [4.4] years vs. 61.3 [2.7] years), body mass index (26.1 [2.6] kg/m2 vs. 31.4 [1.1] kg/m2), and a higher pooled median glycated haemoglobin (9.0 [8.0-10.3]% vs. 7.1 [6.7-7.7]%). Ugandan and Tanzanian participants had lower markers of beta-cell function and insulin resistance when compared with four White European populations.\u0000Conclusion\u0000These findings provide evidence of the ethnic differences in the manifestation of T2D, underscoring the importance of understanding the underlying genetic and environmental factors influencing these phenotypic differences and formulating ethnic-specific approaches for managing and preventing T2D.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140314877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Weight Loss Induced Prediabetes Remission in the Prevention of Type 2 Diabetes - Time to Improve Diabetes Prevention","authors":"Reiner Jumpertz von Schwartzenberg, Elsa Vazquez Arreola, Arvid Sandforth, Robert L Hanson, Andreas L Birkenfeld","doi":"10.1101/2024.03.22.24304576","DOIUrl":"https://doi.org/10.1101/2024.03.22.24304576","url":null,"abstract":"Aims/hypothesis: For individuals with prediabetes, the current American Diabetes Association (ADA) guidelines recommend a body weight loss &gt;7% to prevent the development of type 2 diabetes (T2D) without any glycemic target goals. However, we have recently shown that weight loss induced prediabetes remission reduces relative T2D risk by 73% within the following two years. Therefore, we investigated relative T2D risk reduction in people with weight loss vs those with weight loss and prediabetes remission in an independent cohort: the randomized controlled Diabetes Prevention Program (DPP). Methods: Individuals who lost &gt;7% of their body weight over the first year were included in this analysis. Of these, 416 were assigned to intensive lifestyle intervention and 64 received placebo. Remission of prediabetes was defined by normalization of fasting and 2h glucose during an oral glucose tolerance test and a normalized HbA1c according to ADA criteria. Non-remission was given when at least one of these criteria was not met. We computed Kaplan-Meier curves and compared them using log-rank tests and future T2D risk was assessed by computing the relative risk between groups.\u0000Results: In DPP, 480 individuals achieved a weight loss of &gt;7% and of these 114 additionally achieved prediabetes remission. Over the period of 6 years, those who achieved weight loss and remission had a 66% lower relative risk to develop T2D compared to those who only met the 7% weight loss goal [RR=0.34, 95% CI (0.15, 0.76)]. Similarly, weight loss responders had a lower relative future T2D risk compared to weight loss non-responders [RR=0.28, 95% CI (0.13, 0.64)]. Importantly, there was not a single T2D case in weight loss responders for up to 4 years after the intervention.\u0000Conclusions/interpretation: The combination of achieving weight loss goals and prediabetes remission is most effective in reducing future T2D risk. Thus, beside weight loss goals, interventions in individuals with prediabetes should be continued until prediabetes remission is achieved and this ought to be adapted in current clinical praxis guidelines.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"65 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140301483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbial determinants of dementia risk in subjects of Mexican descent with type 2 diabetes living in South Texas","authors":"Lisa M Matz, Nisarg S Shah, Laura Porterfield, Olivia M Stuyck, Michael D Jochum, Rakez Kayed, Giulio Taglialatela, Randall J Urban, Shelly A Buffington","doi":"10.1101/2024.03.20.24304637","DOIUrl":"https://doi.org/10.1101/2024.03.20.24304637","url":null,"abstract":"Type 2 diabetes (T2D) is a common forerunner of neurodegeneration and dementia, including Alzheimer’s Disease (AD), yet the underlying mechanisms remain unresolved. Individuals of Mexican descent living in South Texas have increased prevalence of comorbid T2D and early onset AD, despite low incidence of the predisposing APOE-e4 variant and an absence of the phenotype among relatives residing in Mexico – suggesting a role for environmental factors in coincident T2D and AD susceptibility. Here, in a small clinical trial, we show dysbiosis of the human gut microbiome could contribute to neuroinflammation and risk for AD in this population. Divergent Gastrointestinal Symptom Rating Scale (GSRS) responses, despite no differences in expressed dietary preferences, provided the first evidence for altered gut microbial ecology among T2D subjects (sT2D) versus population-matched healthy controls (HC). Metataxonomic 16S rRNA sequencing of participant stool revealed a decrease in alpha diversity of sT2D versus HC gut communities and identified BMI as a driver of gut community structure. Linear discriminant analysis effect size (LEfSe) identified a significant decrease in the relative abundance of the short-chain fatty acid-producing taxa Lachnospiraceae, Faecalibacterium, and Alistipes and an increase in pathobionts Escherichia-Shigella, Enterobacter, and Clostridia innocuum among sT2D gut microbiota, as well as differentially abundant gene and metabolic pathways. These results suggest characterization of the gut microbiome of individuals with T2D could identify key actors among “disease state” microbiota which may increase risk for or accelerate the onset of neurodegeneration. Furthermore, they identify candidate microbiome-targeted approaches for prevention and treatment of neuroinflammation in AD.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140198151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison between topical Platelet Rich Plasma and Normal Saline dressing, in conjunction with Total Contact Casting in Treatment of Diabetic Foot Ulcer- a Randomized Control Trial","authors":"Subha Das, Sanyal Kumar, Sanjay Kumar Pandey, Anjani Kumar, Niraj Kumar, Ranjeet Kumar","doi":"10.1101/2024.03.20.24304330","DOIUrl":"https://doi.org/10.1101/2024.03.20.24304330","url":null,"abstract":"Introduction Wound care, which includes cleaning and fostering a moist wound healing environment, play a crucial role in the management of diabetic foot ulcers.. Total-contact casts are widely used as the most effective external technique for off-loading plantar ulcers. This study compared the effectiveness of PRP and normal saline dressings in conjunction with TCC. Methods 36 patients with diabetic foot ulcers were divided into two groups using computer generated randomization into PRP and NS groups with 18 patients in each group. The PRP group was given autologous PRP, and the NS group was given wet dressing with NS, following which TCC was applied in each case for off-loading. Follow-up was performed every 15 days for 90 days. In each follow-up measurement and TCC application, the time to heal and PUSH score was used to measure the condition of the wound. Results\u0000In the PRP group, the mean wound size 8.28 SD 1.18 and the mean Push tool total 13.44 SD 0.98 at base line which gradually decreased, and finally, on day 90, it was reduced to 0.61 SD 1.20 and 1.89 SD 3.68, respectively. In NS group the mean wound size 8.45 SD 1.13 and mean Push tool total 13.50 SD 0.92 at baseline which was gradually decreased and finally at day 90 it was reduced to 1.58 SD 1.55 and 4.61 SD 4.37 respectively. A significant difference was observed in both groups during the final evaluation. Compared with the NS group, the PRP group showed greater improvement. Conclusion Both autologous PRP and NS are effective in treating DFU, when used along with TCC. However, PRP therapy is better at reducing the healing time and hospital visits.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140198320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The iDiabetes Platform: Enhanced Phenotyping of Patients with Diabetes for Precision Diagnosis, Prognosis and Treatment - study protocol for a cluster-randomised controlled study","authors":"YeunYi Lin, Damien Leith, Michael Abbott, Rachael Barrett, Samira Bell, Tim J Croudace, Scott G Cunningham, John F Dillon, Peter T Donnan, Albert Farre, Rodolfo Hernandez, Chim C Lang, Stephanie McKenzie, Ify R Mordi, Susan Morrow, H Cameron Munro, Mandy Ryan, Huan Wang, Mya Win, Ewan R. Pearson","doi":"10.1101/2024.03.19.24304468","DOIUrl":"https://doi.org/10.1101/2024.03.19.24304468","url":null,"abstract":"Introduction and Aim Diabetes is a global health emergency with increasing prevalence and diabetes-associated morbidity and mortality. One of the challenges in optimising diabetes care is translating research advances in this heterogenous disease into routine clinical care. A potential solution is the introduction of precision medicine approaches into diabetes care. We aim to develop a digital platform called intelligent Diabetes (iDiabetes) to support a precision diabetes care model in Scotland and assess its impact on the primary composite outcome of all-cause mortality, hospitalisation rate, renal function decline and glycaemic control. Methods and Analysis The impact of iDiabetes will be evaluated through a cluster-randomised controlled study, recruiting up to 22,500 patients with diabetes. Primary care general practices (GP) in the National Health Service Scotland Tayside Health Board are the units (clusters) of randomisation. Each primary care GP will form one cluster (approximately 400 patients per cluster), with up to 60 clusters recruited. Randomisation will be to iDiabetes (guideline support), iDiabetesPlus or usual diabetes care (control arm). Patients of participating primary care GPs are automatically enrolled to the study when they attend for their annual diabetes screening or are newly diagnosed with diabetes. A composite hierarchical primary outcome, evaluated using Win-Ratio statistical methodology, will consists of (I) all-cause mortality, (II) all-cause hospitalisation rate, (III) proportion with &gt;40% eGFR reduction from baseline or new development of end-stage renal disease, (IV) proportion with absolute HbA1C reduction &gt;0.5%. Comprehensive qualitative and health economic analyses will be conducted, assessing the cost-effectiveness, budget impact and user acceptability of the iDiabetes platform. Ethics and Dissemination This study was reviewed by the NHS HRA and given a favourable opinion by a Research Ethics Committee (reference:23/ES/0008). Study findings will be disseminated via publications and presented at scientific conferences. Findings will be shared with patients and the public on the study website and social media. Study registration ISRCTN18000901\u0000Study Sponsor University of Dundee, no. 2-026-22. Contact: tascgovernance@dundee.ac.uk\u0000Protocol version: V3.0, 22/09/2023","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140198237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CHARACTERIZATION OF ACROMEGALY ACCORDING TO TUMOR SIZE AT DIAGNOSIS","authors":"Leticia Marinho Del Corso, Vicente Florentino Castaldo Andrade, Solena Ziemer Kusma Fidalski, Cesar Luiz Boguszewski","doi":"10.1101/2024.03.19.24304552","DOIUrl":"https://doi.org/10.1101/2024.03.19.24304552","url":null,"abstract":"Purpose: To evaluate the clinical, laboratory, radiological, therapeutic, and prognostic characteristics of patients with acromegaly according to the size of the growth hormone (GH)-secreting pituitary adenoma at diagnosis. Patients and Methods: Observational, retrospective, single-center study of patients with acromegaly followed at a tertiary center. Data from medical records were evaluated regarding age, symptoms, presence of arterial hypertension, type 2 diabetes mellitus, hypopituitarism, size of the initial lesion, invasiveness (cavernous sinus invasion), T2-weighted magnetic resonance imaging signal intensity, GH and insulin-like growth factor type 1 (IGF-1) levels, treatment performed [surgery, use of somatostatin receptor ligands (SRL), pegvisomant, cabergoline and bromocriptine and radiotherapy] and response to surgical or adjuvant treatment (normal levels of GH and/or IGF-1 after each treatment instituted).Patients were divided into groups according to the size of the adenoma at diagnosis (group I = smaller than 10 mm, II = 10-19 mm, III = 20-29 mm, IV = 30-39 mm and V = greater than 40 mm), and comparisons were made between the 5 groups and two-by-two comparisons. Results: 117 patients were studied (59 women, age at diagnosis 43 SD 13 years). Group I consisted of 11 patients (9%), group II of 54 (46%), group III of 34 (29%), group IV of 10 (9%) and group V of 8 patients (7%). The prevalence of hypertension, diabetes mellitus and hypopituitarism were 49%, 25% and 28%, respectively. Hypopituitarism, invasiveness, and the use of SRL had their prevalence increased according to the size of the adenoma, as well as GH levels. Age, on the other hand, showed a negative correlation with tumor size, and group I was older when compared to the group with macroadenoma. The ROC curves showed that in relation to the size of the adenoma at diagnosis, most of the outcomes evaluated (hypopituitarism, invasiveness, radiotherapy, use of SRL, use of medications other than SRL, disease control after surgery) occurred with a tumor diameter of around 20 mm. Conclusion: Our study demonstrated that microadenomas and macroadenomas smaller than 20 mm are associated with lower morbidity and better therapeutic response in acromegaly. From a tumor diameter of 20 mm, there was no significant difference in the clinical, therapeutic and prognostic behavior of GH-secreting pituitary adenomas.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"65 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140198234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterogeneity in elevated glucose and A1C as predictors of the prediabetes to diabetes transition: Framingham Heart Study, Multi-Ethnic Study on Atherosclerosis, Jackson Heart Study, and Atherosclerosis Risk In Communities","authors":"Chirag J Patel, John PA Ioannidis, Edward W Gregg, Ramachandran S Vasan, Arjun K Manrai","doi":"10.1101/2024.03.16.24304398","DOIUrl":"https://doi.org/10.1101/2024.03.16.24304398","url":null,"abstract":"Aims/hypothesis: There are a number of glycemic definitions for prediabetes; however, the\u0000heterogeneity in diabetes transition rates from prediabetes across different glycemic definitions in major US cohorts has been unexplored. We hypothesize that a significant source of variation in the transition rate are cohorts themselves. We estimate the variability in risk and relative risk of diabetes based on diagnostic criteria like fasting glucose and hemoglobin A1C% (HbA1c%).\u0000Methods: We estimated transition rate from prediabetes, as defined by fasting glucose between 100-125 and/or 110-125 mg/dL, and HbA1c% between 5.7-6.5% in participant data from the Framingham Heart Study (FHS) Generation 2, FHS Generation 3, Multi-Ethnic Study on Atherosclerosis, Atherosclerosis Risk in Communities, and the Jackson Heart Study. We estimated the heterogeneity and prediction interval across cohorts, stratifying by age, sex, and body mass index. Among individuals with prediabetes, we estimated the relative risk for obesity, blood pressure, education, age, and sex for diabetes.\u0000Results: There is substantial heterogeneity in diabetes transition rates across cohorts and prediabetes definitions with large prediction intervals. We observed the individuals with fasting glucose of 100-125 range from 4-14% per 100 person years and 110-125 mg/dL ranging from 2-18 per 100 person-years. For HbA1C between 5.7-6.5%, the transition rate ranged from 2.5-11 per 100 person years (I2 for heterogeneity was greater than 93% for all definitions). Obesity and hypertension did not explain the differences in risk.\u0000Conclusion: The absolute transition rate from prediabetes to diabetes significantly depends on both cohort and prediabetes definitions.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"153 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140170085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}